Literature DB >> 32102878

The High Content of Fructose in Human Semen Competitively Inhibits Broad and Potent Antivirals That Target High-Mannose Glycans.

Jacklyn Johnson1, Manuel G Flores1, John Rosa1, Changze Han1, Alicia M Salvi2, Kris A DeMali2, Jennifer R Jagnow3, Amy Sparks3, Hillel Haim4.   

Abstract

Semen is the primary transmission vehicle for various pathogenic viruses. Initial steps of transmission, including cell attachment and entry, likely occur in the presence of semen. However, the unstable nature of human seminal plasma and its toxic effects on cells in culture limit the ability to study in vitro virus infection and inhibition in this medium. We found that whole semen significantly reduces the potency of antibodies and microbicides that target glycans on the envelope glycoproteins (Envs) of HIV-1. The extraordinarily high concentration of the monosaccharide fructose in semen contributes significantly to the effect by competitively inhibiting the binding of ligands to α1,2-linked mannose residues on Env. Infection and inhibition in whole human seminal plasma are accurately mimicked by a stable synthetic simulant of seminal fluid that we formulated. Our findings indicate that, in addition to the protein content of biological secretions, their small-solute composition impacts the potency of antiviral microbicides and mucosal antibodies.IMPORTANCE Biological secretions allow viruses to spread between individuals. Each type of secretion has a unique composition of proteins, salts, and sugars, which can affect the infectivity potential of the virus and inhibition of this process. Here, we describe HIV-1 infection and inhibition in whole human seminal plasma and a synthetic simulant that we formulated. We discovered that the sugar fructose in semen decreases the activity of a broad and potent class of antiviral agents that target mannose sugars on the envelope protein of HIV-1. This effect of semen fructose likely reduces the efficacy of such inhibitors to prevent the sexual transmission of HIV-1. Our findings suggest that the preclinical evaluation of microbicides and vaccine-elicited antibodies will be improved by their in vitro assessment in synthetic formulations that simulate the effects of semen on HIV-1 infection and inhibition.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  HIV-1; antibodies; high-mannose glycans; human semen; lectins; microbicides; seminal plasma simulant; sexual transmission

Year:  2020        PMID: 32102878      PMCID: PMC7163146          DOI: 10.1128/JVI.01749-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  106 in total

1.  Time frames for neutralization during the human immunodeficiency virus type 1 entry phase, as monitored in synchronously infected cell cultures.

Authors:  Hillel Haim; Israel Steiner; Amos Panet
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

2.  Origin of the HIV-susceptible human CD4+ cell line H9.

Authors:  D L Mann; S J O'Brien; D A Gilbert; Y Reid; M Popovic; E Read-Connole; R C Gallo; A F Gazdar
Journal:  AIDS Res Hum Retroviruses       Date:  1989-06       Impact factor: 2.205

3.  Continuous measurement by radio-telemetry of vaginal pH during human coitus.

Authors:  C A Fox; S J Meldrum; B W Watson
Journal:  J Reprod Fertil       Date:  1973-04

Review 4.  HIV broadly neutralizing antibody targets.

Authors:  Constantinos Kurt Wibmer; Penny L Moore; Lynn Morris
Journal:  Curr Opin HIV AIDS       Date:  2015-05       Impact factor: 4.283

5.  Effects of multiple ejaculations after extended periods of sexual abstinence on total, motile and normal sperm numbers, as well as accessory gland secretions, from healthy normal and oligozoospermic men.

Authors:  T G Cooper; C Keck; U Oberdieck; E Nieschlag
Journal:  Hum Reprod       Date:  1993-08       Impact factor: 6.918

6.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

Authors:  D R Burton; J Pyati; R Koduri; S J Sharp; G B Thornton; P W Parren; L S Sawyer; R M Hendry; N Dunlop; P L Nara
Journal:  Science       Date:  1994-11-11       Impact factor: 47.728

7.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.

Authors:  A Trkola; M Purtscher; T Muster; C Ballaun; A Buchacher; N Sullivan; K Srinivasan; J Sodroski; J P Moore; H Katinger
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

8.  Design and expression of a dimeric form of human immunodeficiency virus type 1 antibody 2G12 with increased neutralization potency.

Authors:  Anthony P West; Rachel P Galimidi; Christopher P Foglesong; Priyanthi N P Gnanapragasam; Kathryn E Huey-Tubman; Joshua S Klein; Maria D Suzuki; Noreen E Tiangco; Jost Vielmetter; Pamela J Bjorkman
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

9.  Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae.

Authors:  Barry R O'Keefe; Barbara Giomarelli; Dale L Barnard; Shilpa R Shenoy; Paul K S Chan; James B McMahon; Kenneth E Palmer; Brian W Barnett; David K Meyerholz; Christine L Wohlford-Lenane; Paul B McCray
Journal:  J Virol       Date:  2009-12-23       Impact factor: 5.103

10.  Human semen contains exosomes with potent anti-HIV-1 activity.

Authors:  Marisa N Madison; Richard J Roller; Chioma M Okeoma
Journal:  Retrovirology       Date:  2014-11-19       Impact factor: 4.602

View more
  4 in total

1.  Evaluation of the novel vaginal contraceptive agent PPCM in preclinical studies using sperm hyaluronan binding and acrosome status assays.

Authors:  Barbara B North; Mary B Weitzel; Donald P Waller; William X Birch; Kenneth A Feathergill; Lynn A Birch; Christopher J De Jonge; Gail S Prins
Journal:  Andrology       Date:  2021-10-04       Impact factor: 4.456

2.  Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein.

Authors:  Hanora A Van Ert; Dana W Bohan; Kai Rogers; Mohammad Fili; Roberth A Rojas Chávez; Enya Qing; Changze Han; Spencer Dempewolf; Guiping Hu; Nathan Schwery; Kristina Sevcik; Natalie Ruggio; Devlin Boyt; Michael A Pentella; Tom Gallagher; J Brooks Jackson; Anna E Merrill; C Michael Knudson; Grant D Brown; Wendy Maury; Hillel Haim
Journal:  Microbiol Spectr       Date:  2022-01-26

3.  Phosphatidylserine receptors enhance SARS-CoV-2 infection.

Authors:  Dana Bohan; Hanora Van Ert; Natalie Ruggio; Kai J Rogers; Mohammad Badreddine; José A Aguilar Briseño; Jonah M Elliff; Roberth Anthony Rojas Chavez; Boning Gao; Tomasz Stokowy; Eleni Christakou; Petri Kursula; David Micklem; Gro Gausdal; Hillel Haim; John Minna; James B Lorens; Wendy Maury
Journal:  PLoS Pathog       Date:  2021-11-19       Impact factor: 6.823

Review 4.  NMR spectroscopy spotlighting immunogenicity induced by COVID-19 vaccination to mitigate future health concerns.

Authors:  Sher Ali; Štěpánka Nedvědová; Gul Badshah; Muhammad S Afridi; Lívia M Dutra; Umar Ali; Samara G Faria; Frederico L F Soares; Rafi U Rahman; Fernando A C Q Cançado; Micheli M C C Aoyanagi; Lucas G D Freire; Alan D C Santos; Andersson Barison; Carlos A F Oliveira
Journal:  Curr Res Immunol       Date:  2022-08-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.